← Leaderboards
Eric Alejandro Sweet-Cordero
University Of California, San Francisco
$20,798,239
Attributed
$31,795,700
Total exposure
15
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.4M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$31,795,700 · 15
By mechanism
R01$22,057,842 · 10
U01$3,153,893 · 1
U54$2,779,554 · 1
T32$2,756,920 · 1
K08$678,705 · 1
P30$368,786 · 1
Top collaborators
- Michael C Bassik10 shared
- Peter Kent Jackson10 shared
- Kimberly Stegmaier9 shared
- Atul J Butte5 shared
- Jennifer R Cochran5 shared
- Julien Sage5 shared
- David H Haussler4 shared
- Fan Yang3 shared
Most similar at University Of California, San Francisco
Same institution · by research overlap
- William A Weiss$31,543,847
- Isha Himani Jain$5,252,807
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsMalignant NeoplasmsTumorGenesGeneticGenomicsFunctional GenomicsMediatingOncogenicIn VivoMutationMolecularCell LineMouse ModelBiochemicalMalignant Neoplasm Of LungEventPathway InteractionsProteinsTumorigenesisBiologicalMutateGene ExpressionXenograft Procedure
Grant awards (76)
Engineering 3D Osteosarcoma Models to Elucidate Biology and Inform Drug Discovery$643,432
R01 · FY2025 · CA
Identifying and Targeting Mechanisms for Membrane Signaling in Human Cancer$554,274
R01 · FY2025 · CA · contact PI
Epigenetic analysis of osteosarcoma to define subclasses relevant to chemoresistance and metastasis$540,090
R01 · FY2025 · CA · contact PI
Research Training in Childhood Cancer$351,001
T32 · FY2025 · CA · contact PI
Pediatric Malignancies Program$185,525
P30 · FY2025 · CA · contact PI
Engineering 3D Osteosarcoma Models to Elucidate Biology and Inform Drug Discovery$614,400
R01 · FY2024 · CA
Development of Advanced Preclinical Models for Pediatric Solid Tumors$571,418
R01 · FY2024 · CA · contact PI
Identifying and Targeting Mechanisms for Membrane Signaling in Human Cancer$526,562
R01 · FY2024 · CA · contact PI
Research Training in Childhood Cancer$410,448
T32 · FY2024 · CA · contact PI
Pediatric Malignancies Program$183,261
P30 · FY2024 · CA · contact PI
Engineering 3D Osteosarcoma Models to Elucidate Biology and Inform Drug Discovery$666,209
R01 · FY2023 · CA
Development of Advanced Preclinical Models for Pediatric Solid Tumors$589,462
R01 · FY2023 · CA · contact PI
Identifying and Targeting Mechanisms for Membrane Signaling in Human Cancer$543,188
R01 · FY2023 · CA · contact PI
Research Training in Childhood Cancer$379,393
T32 · FY2023 · CA · contact PI
Development of Advanced Preclinical Models for Pediatric Solid Tumors$589,462
R01 · FY2022 · CA · contact PI
Development of novel protein-based therapeutics for lung cancer$552,581
R01 · FY2022 · CA · contact PI
Identifying and Targeting Mechanisms for Membrane Signaling in Human Cancer$543,190
R01 · FY2022 · CA · contact PI
Research Training in Childhood Cancer$359,703
T32 · FY2022 · CA · contact PI
Development of Advanced Preclinical Models for Pediatric Solid Tumors$601,492
R01 · FY2021 · CA · contact PI
Identifying and Targeting Mechanisms for Membrane Signaling in Human Cancer$569,651
R01 · FY2021 · CA · contact PI
Development of novel protein-based therapeutics for lung cancer$563,856
R01 · FY2021 · CA · contact PI
Dissecting the Pathogenesis of Ewing Sarcoma with Integrative Genomics$396,547
R01 · FY2021 · CA
Role of long non-coding RNAs in sarcoma pathogenesis$393,107
R01 · FY2021 · CA · contact PI
Research Training in Childhood Cancer$322,582
T32 · FY2021 · CA · contact PI
Development of Advanced Preclinical Models for Pediatric Solid Tumors$616,057
R01 · FY2020 · CA · contact PI
Development of novel protein-based therapeutics for lung cancer$563,401
R01 · FY2020 · CA · contact PI
Dissecting the Pathogenesis of Ewing Sarcoma with Integrative Genomics$479,795
R01 · FY2020 · CA
Role of long non-coding RNAs in sarcoma pathogenesis$376,004
R01 · FY2020 · CA · contact PI
Research Training in Childhood Cancer$326,022
T32 · FY2020 · CA · contact PI
Development of novel protein-based therapeutics for lung cancer$557,605
R01 · FY2019 · CA · contact PI
Using Protein Interaction Networks and Combinatorial Screens to target KRAS driven cancer$538,965
U01 · FY2019 · CA
Dissecting the Pathogenesis of Ewing Sarcoma with Integrative Genomics$384,651
R01 · FY2019 · CA
Role of long non-coding RNAs in sarcoma pathogenesis$338,725
R01 · FY2019 · CA · contact PI
Research Training in Childhood Cancer$312,882
T32 · FY2019 · CA · contact PI
Dissecting the Pathogenesis of Ewing Sarcoma with Integrative Genomics$119,844
R01 · FY2019 · CA
Role of long non-coding RNAs in sarcoma pathogenesis$18,264
R01 · FY2019 · CA · contact PI
Core C: Preclinical Models Core$2,779,554
U54 · FY2018 · CA · contact PI
Using Protein Interaction Networks and Combinatorial Screens to target KRAS driven cancer$623,508
U01 · FY2018 · CA
Development of novel protein-based therapeutics for lung cancer$603,877
R01 · FY2018 · CA · contact PI
Role of long non-coding RNAs in sarcoma pathogenesis$400,745
R01 · FY2018 · CA · contact PI
Dissecting the Pathogenesis of Ewing Sarcoma with Integrative Genomics$396,547
R01 · FY2018 · CA
Research Training in Childhood Cancer$294,889
T32 · FY2018 · CA · contact PI
Dissecting the Pathogenesis of Ewing Sarcoma with Integrative Genomics$228,600
R01 · FY2018 · CA
Sweet-Cordero_Diversity Supplement_Due 03/30/18$61,794
R01 · FY2018 · CA · contact PI
Dissecting the Pathogenesis of Ewing Sarcoma with Integrative Genomics$40,302
R01 · FY2018 · CA
Using Protein Interaction Networks and Combinatorial Screens to target KRAS driven cancer$663,150
U01 · FY2017 · CA
Role of long non-coding RNAs in sarcoma pathogenesis$416,546
R01 · FY2017 · CA · contact PI
Dissecting the Pathogenesis of Ewing Sarcoma with Integrative Genomics$396,547
R01 · FY2017 · CA
Dissecting the Pathogenesis of Ewing Sarcoma with Integrative Genomics$228,600
R01 · FY2017 · CA
Using Protein Interaction Networks and Combinatorial Screens to target KRAS driven cancer$663,814
U01 · FY2016 · CA
Novel effectors of Kras in oncogenesis, senescence and tumor progression$173,517
R01 · FY2016 · CA · contact PI
Novel effectors of Kras in oncogenesis, senescence and tumor progression$98,060
R01 · FY2016 · CA · contact PI
Using Protein Interaction Networks and Combinatorial Screens to target KRAS driven cancer$664,456
U01 · FY2015 · CA
Mechanisms of chemotherapy response and tumor re-initiation in lung cancer$340,622
R01 · FY2015 · CA · contact PI
Novel effectors of Kras in oncogenesis, senescence and tumor progression$271,154
R01 · FY2015 · CA · contact PI
Mechanisms of chemotherapy response and tumor re-initiation in lung cancer$21,424
R01 · FY2015 · CA · contact PI
Mechanisms of chemotherapy response and tumor re-initiation in lung cancer$329,693
R01 · FY2014 · CA · contact PI
Novel effectors of Kras in oncogenesis, senescence and tumor progression$262,627
R01 · FY2014 · CA · contact PI
Mechanisms of chemotherapy response and tumor re-initiation in lung cancer$34,819
R01 · FY2014 · CA · contact PI
Mechanisms of chemotherapy response and tumor re-initiation in lung cancer$318,863
R01 · FY2013 · CA · contact PI
Novel effectors of Kras in oncogenesis, senescence and tumor progression$254,137
R01 · FY2013 · CA · contact PI
Comparative functional genomics for lung cancer gene discovery$521,052
R01 · FY2012 · CA · contact PI
Mechanisms of chemotherapy response and tumor re-initiation in lung cancer$338,566
R01 · FY2012 · CA · contact PI
Novel effectors of Kras in oncogenesis, senescence and tumor progression$269,988
R01 · FY2012 · CA · contact PI
Comparative functional genomics for lung cancer gene discovery$536,945
R01 · FY2011 · CA · contact PI
Mechanisms of chemotherapy response and tumor re-initiation in lung cancer$337,952
R01 · FY2011 · CA · contact PI
Comparative functional genomics for lung cancer gene discovery$569,332
R01 · FY2010 · CA · contact PI
Identification of Novel Kras Effector Pathways in Lung Cancer$272,150
R01 · FY2010 · CA · contact PI
Comparative functional genomics for lung cancer gene discovery$573,992
R01 · FY2009 · CA · contact PI
Identification of Novel Kras Effector Pathways in Lung Cancer$271,639
R01 · FY2009 · CA · contact PI
Comparative functional genomics for lung cancer gene discovery$574,485
R01 · FY2008 · CA · contact PI
Tumor progression in a mouse model of lung cancer$135,837
K08 · FY2007 · CA · contact PI
Tumor progression in a mouse model of lung cancer$135,837
K08 · FY2006 · CA · contact PI
Tumor progression in a mouse model of lung cancer$135,837
K08 · FY2005 · CA
Tumor progression in a mouse model of lung cancer$135,837
K08 · FY2004 · CA
Tumor progression in a mouse model of lung cancer$135,357
K08 · FY2003 · CA